Welcome to our dedicated page for Argenx Se news (Ticker: ARGX), a resource for investors and traders seeking the latest updates and insights on Argenx Se stock.
argenx SE (ARGX) is a global immunology company listed on Euronext and Nasdaq that focuses on severe autoimmune diseases through antibody-based medicines. Its news flow centers on clinical data, regulatory milestones, commercial performance and strategic updates related to its FcRn-targeting medicine VYVGART and a broader pipeline of experimental antibodies.
Investors and healthcare observers following ARGX news can read about regulatory interactions such as the U.S. Food and Drug Administration’s acceptance for priority review of a supplemental Biologics License Application (sBLA) for VYVGART in acetylcholine receptor antibody seronegative generalized myasthenia gravis (gMG). Company announcements also cover Phase 3 trial readouts, including the ADAPT SERON study in seronegative gMG and other registrational programs across neuromuscular and autoimmune indications.
argenx regularly reports preliminary and quarterly financial results, highlighting global product net sales from the VYVGART franchise and outlining strategic priorities tied to its long-term "Vision 2030". News items describe the expansion of VYVGART and VYVGART Hytrulo across gMG, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenia (ITP) in certain regions, as well as progress with pipeline candidates such as empasiprubart and ARGX-119.
Corporate news includes leadership transitions, conference presentations at major medical and investor meetings, and updates from the company’s Immunology Innovation Program (IIP). For readers interested in ARGX stock and the evolution of its immunology franchise, this news feed provides a consolidated view of clinical, regulatory, commercial and corporate developments as disclosed in argenx press releases and related filings.
argenx (Euronext & Nasdaq: ARGX) announced its Annual General Meeting of shareholders will be held at 13:00 CET on Wednesday, May 6, 2026 at the Hilton Amsterdam Schiphol.
Agenda items include adoption of the 2025 annual accounts, advisory vote on the 2025 remuneration report, discharge of directors, share issuance authorization and several board appointments and reappointments. Documents and e-voting information are available on the argenx website and via ABN AMRO e-voting; shareholders are encouraged to vote by proxy. For copies contact legal@argenx.com.
argenx (NASDAQ: ARGX) will present clinical and real-world data for VYVGART and pipeline candidates at the 2026 AAN Annual Meeting (April 18–22, 2026) in Chicago.
Highlights include positive Phase 3 ADAPT OCULUS results in ocular myasthenia gravis, ADAPT SERON data showing efficacy in AChR‑Ab–negative gMG subtypes, CIDP biomarker and ADHERE analyses, and ARGX‑119 Phase 1b safety and functional improvements.
argenx (NASDAQ:ARGX) reported strong 2025 results: $4.2 billion in full‑year product net sales (≈+90% YoY) and ~$1.1 billion operating income, its first profitable year on an operating basis. The company announced positive ADAPT OCULUS oMG data and a PDUFA target date of May 10, 2026 for seronegative gMG.
argenx reiterated Vision 2030 goals, growth plans for the VYVGART franchise, multiple upcoming registrational readouts through 2026–2027, and expansion of its FcRn and broader immunology pipeline.
argenx (NASDAQ:ARGX) reported positive topline results from the Phase 3 ADAPT OCULUS trial of VYVGART in ocular myasthenia gravis (oMG) on February 26, 2026. The study met its primary endpoint (p=0.012) with a mean MGII PRO ocular score improvement of 4.04 for VYVGART vs 1.99 for placebo at Week 4.
Patients showed marked reductions in diplopia and ptosis; safety was consistent with prior studies and no new concerns were identified. Results support a planned sBLA submission to the FDA to expand the VYVGART label into oMG.
argenx (Euronext & Nasdaq: ARGX) announced that Karen Massey, Chief Operating Officer, will speak in a fireside chat at the TD Cowen 46th Annual Healthcare Conference on Monday, March 2, 2026 at 11:50 a.m. ET.
According to the company, a live webcast will be available on the Investors section of the argenx website, with a replay accessible for approximately 30 days after the presentation.
argenx (NASDAQ:ARGX) will report full year 2025 financial results and deliver a fourth quarter business update on Thursday, February 26, 2026 at 2:30 PM CET (8:30 AM ET).
The company said a live audio webcast and conference call will be available via the Investors section at argenx.com/investors, with a replay available for about one year. Dial-in access code: 3810049.
argenx (NASDAQ:ARGX) announced the FDA accepted a supplemental BLA for VYVGART in AChR‑Ab seronegative generalized myasthenia gravis with Priority Review and a PDUFA target action date of May 10, 2026. The sBLA is supported by Phase 3 ADAPT SERON (n=119), which met its primary endpoint (p=0.0068) with a mean MG‑ADL improvement of 3.35 points at week 4 versus placebo. Efficacy signals and MG‑ADL/QMG improvements were seen across MuSK+, LRP4+, and triple seronegative subgroups. VYVGART safety was consistent with its established profile and no new safety concerns were identified.
argenx (ARGX) reported preliminary full-year 2025 global product net sales of $4.15 billion (approximately +90% YoY) and fourth-quarter sales of $1.29 billion. The company says ~19,000 patients are on VYVGART treatment and expects multiple registrational readouts in 2026, including the first for empasiprubart and topline ocular MG results in Q1 2026. argenx plans to have 10 clinical-stage molecules by end-2026 and to advance FcRn franchise candidates (ARGX-213, ARGX-124). A potential label expansion for seronegative gMG via an sBLA could lead to a launch by end-2026 if approved. Management succession and other corporate changes are subject to shareholder approval in May 2026.
argenx (Euronext & Nasdaq: ARGX) announced that CEO Tim Van Hauwermeiren will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT.
A live webcast will be available on the company's Investors website at argenx.com/investors, and a replay will be accessible on the site for approximately 30 days after the presentation.
argenx (NASDAQ:ARGX) announced a leadership transition effective January 5, 2026: Chief Operating Officer Karen Massey will become Chief Executive Officer and Executive Director, and current CEO Tim Van Hauwermeiren will move to Non‑Executive Director and Chairman of the Board.
The Board said Tim will succeed Peter Verhaeghe, who is retiring after serving since 2008. The changes are subject to shareholder approval at the Annual General Meeting on May 6, 2026, providing a comprehensive transition period.